Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.55 |
| ▸ | CPA3 | P15088 | 3/20 | 0.52 |
| ▸ | CPA1 | P15085 | 3/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.52 |
| ▸ | CPB1 | P15086 | 1/20 | 0.52 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.52 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.51 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.51 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 2/20 | 0.51 |
| ▸ | ALPI | P09923 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | XIAP | P98170 | 1/20 | 0.50 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | ANPEP | P15144 | 1/20 | 0.46 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5052372 | 0.88 | CYP1A2 (0.68) | CYP1A2EPHX1CPA3CPA1FOLH1 | |
| SCHEMBL3662060 | 0.85 | CYP1A2 (0.55) | CYP1A2EPHX1CPA3CPA1FOLH1 | |
| SCHEMBL2846532 | 0.85 | CYP1A2 (0.55) | CYP1A2EPHX1CPA3CPA1FOLH1 | |
| SCHEMBL491524 | 0.84 | CYP1A2 (0.83) | CYP1A2CPA3CPA1FOLH1CPB1 | |
| SCHEMBL4886609 | 0.84 | CYP1A2 (0.69) | CYP1A2CPA3CPA1FOLH1CPB1 | |
| SCHEMBL265514 | 0.84 | CYP1A2 (0.83) | CYP1A2CPA3CPA1FOLH1CPB1 | |
| SCHEMBL265063 | 0.84 | CYP1A2 (0.83) | CYP1A2CPA3CPA1FOLH1CPB1 | |
| SCHEMBL12118655 | 0.83 | EPHX1 (0.43) | CYP1A2EPHX1PPARGEPHX2ALDH1A1 | |
| SCHEMBL6609906 | 0.82 | CYP1A2 (0.61) | CYP1A2EPHX1CPA3CPA1FOLH1 | |
| SCHEMBL7353741 | 0.82 | CYP1A2 (0.61) | CYP1A2EPHX1CPA3CPA1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12351580-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC. (US) | 2025-07-08 | — | — | US | disclosed |
| CN-113329746-B | Compounds for the treatment or prophylaxis of pain, inflammation and/or autoimmunity | 诺瓦麦有限公司 | 2025-05-02 | — | — | CN | disclosed |
| US-20250034084-A1 | COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING MYCOSIS | AMTIXBIO CO., LTD. (KR) | 2025-01-30 | — | — | US | disclosed |
| US-20250034085-A1 | COMPOSITION AND METHODS FOR PREVENTING OR TREATING PHYTOPATHOGENIC FUNGAL INFECTION | AMTIXBIO CO., LTD. (KR) | 2025-01-30 | — | — | US | disclosed |
| US-20250034083-A1 | METHODS FOR PREPARING BENZYLOXYBENZYLAMINE AMINO ACID DERIVATIVES | AMTIXBIO CO., LTD. (KR) | 2025-01-30 | — | — | US | disclosed |
| US-20250034082-A1 | FUNCTIONAL DERIVATIVE COMPOUNDS OF ALANINE AND PROLINE AMINO ACIDS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | AMTIXBIO CO., LTD. (KR) | 2025-01-30 | — | — | US | disclosed |
| US-20240067649-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2024-02-29 | — | — | US | disclosed |
| US-11827632-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2023-11-28 | — | — | US | disclosed |
| US-20220289736-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2022-09-15 | — | — | US | disclosed |
| EP-3557997-A1 | MIXTURES OF BEFLUBUTAMID OR OPTICALLY ENRICHED FORMS THEREOF WITH A SECOND HERBICIDE | FMC Corporation (US) | 2019-10-30 | — | — | EP | disclosed |
| CN-101573340-A | Modulators of glucocorticoid receptor AP-1 and/or NF-kB activity and uses thereof | BRISTOL MYERS SQUIBB CO (US) | 2009-11-04 | — | — | CN | disclosed |
| EP-2097385-A1 | 2-[1-PHENYL-5-HYDROXY OR METHOXY-4ALPHA-METHYL-HEXAHYDROCLOPENTA[F]INDAZOL-5-YL]ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS | Merck & Co., Inc. (US) | 2009-09-09 | — | — | EP | disclosed |
| CN-101395154-A | 8-azabicyclo [3.2.1] octane compounds as mu opioid receptor antagonists | THERAVANCE INC (US) | 2009-03-25 | — | — | CN | disclosed |
| WO-2008051532-A1 | 2-[1-PHENYL-5-HYDROXY OR METHOXY-4ALPHA-METHYL-HEXAHYDROCLOPENTA[F]INDAZOL-5-YL]ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS | MERCK & CO., INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| CN-1900080-A | Inhibitors of cruzipain and other cysteine proteases | AMURA THERAPEUTICS LTD (GB) | 2007-01-24 | — | — | CN | disclosed |
| US-7160890-B2 | Compounds specific to adenosine A3 receptor and uses thereof | OSI PHARMACEUTICALS, INC. (US) | 2007-01-09 | — | — | US | disclosed |
| CN-1867581-A | IL-21 derivatives | NOVO NORDISK AS (DK) | 2006-11-22 | — | — | CN | disclosed |
| CN-1269822-C | Inhibitors of kruenza protease and other cysteine proteases | AMURA THERAPEUTICS LTD (GB) | 2006-08-16 | — | — | CN | disclosed |
| EP-1635839-A2 | BENZO[4,5]THIENO[2,3-D]PYRIMIDIN-4-ONES AND THEIR USE IN THERAPY | Solvay Pharmaceuticals B.V. (NL) | 2006-03-22 | — | — | EP | disclosed |
| WO-2005032527-A2 | BENZO (4, 5) THIENO (2, 3-D) PYRIMIDIN-4-ONES AND THEIR USE IN THERAPY | SOLVAY PHARMACEUTICALS B.V. (NL) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827632-B2 | NLRP3 modulators | NLRP3, NLRP1, NOD1 | CYP1A2 3653/4885EPHX1 1422/4885CPA3 3002/4885 |
| US-20220289736-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, NOD1 | CYP1A2 3653/4885EPHX1 1422/4885CPA3 3002/4885 |
| US-20250034083-A1 | METHODS FOR PREPARING BENZYLOXYBENZYLAMINE AMINO ACID DERIVATIVES | BCAT2, BCAT1, DAO | CYP1A2 313/4885EPHX1 3037/4885CPA3 438/4885 |
| US-12351580-B2 | NLRP3 modulators | NLRP3, NLRP1, NOD1 | CYP1A2 3653/4885EPHX1 1422/4885CPA3 3002/4885 |
| US-20250034082-A1 | FUNCTIONAL DERIVATIVE COMPOUNDS OF ALANINE AND PROLINE AMINO ACIDS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | PEPD, BCAT1, ANPEP | CYP1A2 478/4885EPHX1 3263/4885CPA3 336/4885 |
| US-20240067649-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, NOD1 | CYP1A2 3653/4885EPHX1 1422/4885CPA3 3002/4885 |
| US-20250034084-A1 | COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING MYCOSIS | ERG28, BCAT2, AADAT | CYP1A2 389/4885EPHX1 2350/4885CPA3 339/4885 |
| US-20250034085-A1 | COMPOSITION AND METHODS FOR PREVENTING OR TREATING PHYTOPATHOGENIC FUNGAL INFECTION | PEPD, PREP, ANPEP | CYP1A2 518/4885EPHX1 1811/4885CPA3 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.